S16 Ep3: Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD

What this episode covers

In today’s episode, Christopher Lieu, MD, reviewed current treatment strategies and factors informing sequencing decisions for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Lieu is co-director of the Gastrointestinal Medical Oncology Program, associate director for clinical research, and a professor of medicine in the Department of Medical Oncology at the University of Colorado Cancer Center in Aurora. In our exclusive interview, Dr Lieu explained how treatment priorities are recalibrated to account for changing goals of care when a patient with mCRC reaches the third-line setting; emphasized the importance of molecular retesting in this setting to identify new actionable mutations; and discussed how efforts to shift effective therapies earlier in the treatment course could reduce the need for third-line options in the future.

Distinct summary based on available episode metadata or transcript content.